ibs
William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.
Researchers have found that certain gut bacteria and their metabolites differ between IBS subtypes.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.
Giovanni Barbara, congress chair, explain why it is important to be part of IBS Days 2024.
According to the authors, results suggest that patients with a specific microbial signature have a more favorable response to therapy.
The gut microbiota can be useful to distinguish between IBD and IBS. That's according to a study published in Science Translational Medicine.
